<DOC>
	<DOCNO>NCT00569296</DOCNO>
	<brief_summary>RATIONALE : Giving autologous lymphocyte treat laboratory antibody may stimulate immune system kill tumor cell . Aldesleukin may stimulate lymphocyte kill tumor cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving laboratory-treated autologous lymphocytes together aldesleukin GM-CSF may kill tumor cell . PURPOSE : This phase I trial study side effect best dose laboratory-treated autologous lymphocyte give together aldesleukin GM-CSF treating patient recurrent , refractory , metastatic non-small cell lung cancer . FUNDING SOURCE -- FDA OOPD</brief_summary>
	<brief_title>Laboratory-Treated Autologous Lymphocytes , Aldesleukin , GM-CSF Treating Patients With Recurrent , Refractory , Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety maximum tolerate dose EGFRBi-armed autologous activate T-cells ( ATC ) administer combination low-dose aldesleukin sargramostim ( GM-CSF ) patient recurrent , refractory , extensive ( metastatic ) non-small cell lung cancer ( NSCLC ) . Secondary - Assess clinical outcome base tumor response , overall survival , progression-free survival . - Monitor change sera concentration tumor marker association EGFRBi-armed ATC administration throughout study time point thereafter patient elevated level carcinoembryonic antigen ( CEA ) prior begin study . - Monitor patient serum human anti-mouse antibody ( HAMA ) . - Evaluate immune response , may reflect immune augmentation response EGFRBi-armed ATC infusion , peripheral blood mononuclear cell ( PBMC ) sample well purify immune cell population . - Investigate proliferation response ex vivo stimulation NSCLC tumor-associated antigen , serum cytokine profile ( Th1 v Th2 ) , cytotoxicity patient PBMC , interferon gamma ELISPOTS surrogate marker assess generation EGFR-specific cytotoxic T-lymphocytes ( CTL ) . OUTLINE : Peripheral blood mononuclear cell ( PBMCs ) collect 1 2 leukaphereses generation activate T cell ( ATCs ) . The PBMCs activate OKT3 ( anti-CD3 ) expand aldesleukin 14 day . The ATCs arm EGFRBi . Patients receive EGFRBi-armed autologous ATCs IV 30-60 minute twice weekly 4 week ( total 8 infusion ) absence disease progression unacceptable toxicity . Patients also receive low-dose aldesleukin subcutaneously ( SC ) daily sargramostim ( GM-CSF ) SC twice weekly begin 3 day first ATC infusion continue 1 week last ATC infusion . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Recurrent , refractory , metastatic disease ≥ 1 prior firstline regimen ( chemotherapy radiotherapy ) Documented EGFRpositive disease ( expression level ) immunohistochemistry ( IHC ) ( may base archival sample ) Measurable evaluable disease radiograph , CT scan , MRI , and/or physical exam Appropriate slide primary lesion must available review IHC stain assessment central pathology team No clinical evidence active brain metastasis Patients brain metastasis eligible provide receive definitive radiotherapy chemotherapy and/or undergone surgical resection brain metastases No prior hematological malignancy PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 60100 % OR ECOG PS 02 Life expectancy ≥ 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Granulocytes ≥ 1,000/mm^3 Platelet count ≥ 50,000/mm^3 Hemoglobin ≥ 8 g/dL BUN ≤ 2.0 time normal Serum creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 time normal SGOT ≤ 1.5 time normal ( without liver metastasis ) Hepatitis B surface antigen HIV negative LVEF ≥ 45 % rest ( MUGA ) No evidence depress left ventricular function FEV_1 , DLCO , FVC ≥ 50 % predict value No malignancy , except follow : History curatively treat situ squamous cell carcinoma basal cell carcinoma skin History curatively treat malignancy ( except hematologic origin ) patient remain complete remission &gt; 5 year complete therapy ( documented history , physical exam , tumor marker , radiology scan ) No serious medical psychiatric illness would preclude give informed consent receive intensive treatment No recent myocardial infarction ( within past year ) No current angina/coronary symptom require medication No clinical evidence congestive heart failure require medical management ( irrespective MUGA result ) No systolic blood pressure ( BP ) ≥ 130 mm Hg diastolic BP ≥ 80 mm Hg Patients elevate BP must control antihypertensive medication least 7 day prior first infusion PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior chemotherapy radiotherapy At least 4 week since prior cetuximab small molecule EGFRinhibitors include , limited , gefitinib erlotinib hydrochloride No concurrent radiotherapy No concurrent steroid except treatment adrenal failure , septic shock , pulmonary toxicity hormone nondiseaserelated condition ( e.g. , insulin diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>